Bibliografia
1. Abrams D.I. Integrating cannabis into clinical cancer care. Curr. Oncol., 2016; vol. 23, n. 2: S8-S14.
2. Alloui A., Chassaing C., Schmidt J., Ardid D., Dubray C., Cloarec A., Eschalier A. Paracetamol exerts a spinal, tropisetron-reversible, antinociceptive effect in an inflammatory pain model in rats. Eur. J. Pharmacol., 2002; vol. 443: pp. 71-77.
3. Bello A.M., Dye C. Current perceptions and use of paracetamol in dogs among veterinary surgeons working in the United Kingdom. Vet. Med. Sci., 2023; vol. 9, n. 2: pp. 679-686.
4. Belshaw Z., Asher L., Harvey N.D., Dean R.S. Quality of life assessment in domestic dogs: An evidence-based rapid review. Vet. J., 2015; vol. 206, n. 2: pp. 203-212.
5. Berry S.H. Analgesia in the Perioperative Period. Vet. Clin. North. Am. Small. Anim. Pract., 2015; vol. 45, n. 5 : pp. 1013-1027.
6. Brown D.C., Boston R., Coyne J.C., Farrar J.T. A novel approach to the use of animals in studies of pain: validation of the canine brief pain inventory in canine bone cancer. Pain. Med., 2009; vol. 10, n. 1: pp. 133-142.
7. Bulman-Fleming J.C., Turner T.R., Rosenberg M.P. Evaluation of adverse events in cats receiving long-term piroxicam therapy for various neoplasms. J. Feline Med. Surg., 2010; vol. 12, n. 4: pp. 262-268.
8. Caraceni A., Zecca E., Martini C., De Conno F. Gabapentin as an adjuvant to opioid analgesia for neuropathic cancer pain. J. Pain Symptom Manage., 1999; vol. 17, n. 6: pp. 441-445.
9. Chandrasekharan N.V., Dai H., Roos K.L., Evanson N.K., Tomsik J., Elton T.S., Simmons D.L. COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc. Natl. Acad. Sci. USA., 2002; vol. 99, n. 21: pp. 13926-13931.
10. Cota D., Marsicano G., Lutz B., Vicennati V., Stalla G.K., Pasquali R., Pagotto U. Endogenous cannabinoid system as a modulator of food intake. Int. J. Obes. Relat. Metab. Disord., 2003; vol. 27, n. 3: pp. 289-301.
11. Crociolli G.C., Cassu R.N., Barbero R.C., Rocha T.L., Gomes D.R., Nicácio G.M. Gabapentin as an adjuvant for postoperative pain management in dogs undergoing mastectomy. J. Vet. Med. Sci. 2015; vol. 77, n. 8: pp. 1011-1015.
12. Domínguez-Oliva A., Casas-Alvarado A., Miranda-Cortés A.E., Hernández-Avalos I. Clinical pharmacology of tramadol and tapentadol, and their therapeutic efficacy in different models of acute and chronic pain in dogs and cats. J. Adv. Vet. Anim. Res., 2021; vol. 8, n. 3: pp. 404-422.
13. Donati P.A., Tarragona L., Franco J.V.A., Kreil V., Fravega R., Diaz A., Verdier N., Otero P.E. Efficacy of tramadol for postoperative pain management in dogs: systematic review and meta-analysis. Vet. Anaesth. Analg., 2021; vol. 48, n. 3: pp. 283-296.
14. Doré M. Cyclooxygenase-2 expression in animal cancers. Vet. Pathol., 2011; vol. 48, n. 1: pp. 254-265.
15. Edney A.T.B. Reasons for the euthanasia of dogs and cats. Vet. Rec., 1998; vol.143, n. 4: pp 114.
16. Eigner D.R., Breitreiter K., Carmack T., Cox S., Downing R., Robertson S., Rodan I. 2023 AAFP/IAAHPC feline hospice and palliative care guidelines. J. Feline Med. Surg., 2023; vol. 25, n. 9: 1098612X231201683.
17. Eisenberg E., Pud D. Can patients with chronic neuropathic pain be cured by acute administration of the NMDA receptor antagonist amantadine? Pain, 1998; vol. 74, n. (2-3): pp. 337-339.
18. Eisenberg E., Pud D., Koltun L., Loven D. Effect of early administration of the N-methyl-d-aspartate receptor antagonist amantadine on the development of postmastectomy pain syndrome: a prospective pilot study. J. Pain., 2007; vol. 8, n. 3: pp. 223-229.
19. Fallon M.T. Neuropathic pain in cancer. Br. J. Anaesth. 2013; vol. 111, n. 1: pp. 105-111.
20. Fan T.M., de Lorimier L.P., O'Dell-Anderson K., Lacoste H.I., Charney S.C. Single-agent pamidronate for palliative therapy of canine appendicular osteosarcoma bone pain. J. Vet. Intern. Med., 2007; vol. 21, n. 3: pp. 431-439.
21. Flôr P.B., Yazbek K.V., Ida K.K., Fantoni D.T. Tramadol plus metamizole combined or not with anti-inflammatory drugs is clinically effective for moderate to severe chronic pain treatment in cancer patients. Vet. Anaesth. Analg.. 2013; vol. 40, n. 3: pp. 316-327.
22. Fulmer A.E., Laven L.J., Hill K.E. Quality of Life Measurement in Dogs and Cats: A Scoping Review of Generic Tools. Animals, 2022; vol. 12, n. 3: pp. 400.
23. Guedes A.G.P., Meadows J.M., Pypendop B.H., Johnson E.G., Zaffarano B. Assessment of the effects of gabapentin on activity levels and owner- perceived mobility impairment and quality of life in osteoarthritic geriatric cats. J. Am. Vet. Med. Assoc., 2018; vol. 253, n. 5: pp. 579-585.
24. Hernández-Avalos I., Valverde A., Ibancovichi-Camarillo J.A., Sánchez-Aparicio P., Recillas-Morales S., Osorio-Avalos J., Rodríguez-Velázquez D., Miranda-Cortés A.E. Clinical evaluation of postoperative analgesia, cardiorespiratory parameters and changes in liver and renal function tests of paracetamol compared to meloxicam and carprofen in dogs undergoing ovariohysterectomy. PLoS One., 2020; vol.15, n. 2: e0223697.
25. Hofmeister E.H., Egger C.M. Transdermal fentanyl patches in small animals. J. Am. Anim. Hosp. Assoc., 2004; vol. 40, n. 6: pp. 468-478.
26. Högestätt E.D., Jönsson B.A., Ermund A., Andersson D.A., Björk H., Alexander J.P., Cravatt B.F., Basbaum A.I., Zygmunt P.M.. Conversion of acetaminophen to the bioactive N-acylphenolamine AM404 via fatty acid amide hydrolase-dependent arachidonic acid conjugation in the nervous system. J. Biol. Chem., 2005; vol. 280, n. 36: pp. 31405-31412.
27. Israel F.J., Parker G., Charles M., Reymond L. Lack of benefit from paracetamol (acetaminophen) for palliative cancer patients requiring high-dose strong opioids: a randomized, double-blind, placebo-controlled, crossover trial. J. Pain Symptom Manage., 2010; vol. 39, n. 3: pp. 548-554.
28. Johnson J.R., Lossignol D., Burnell-Nugent M., Fallon M.T. An open-label extension study to investigate the long-term safety and tolerability of THC/CBD oromucosal spray and oromucosal THC spray in patients with terminal cancer-related pain refractory to strong opioid analgesics. J. Pain Symptom. Manage., 2013; vol. 46, n. 2: pp. 207-218.
29. Knapp D.W., Richardson R.C., Chan T.C., Bottoms G.D., Widmer W.R., DeNicola D.B., Teclaw R., Bonney P.L., Kuczek T. Piroxicam therapy in 34 dogs with transitional cell carcinoma of the urinary bladder. J. Vet. Intern. Med., 1994; vol. 8, n. 4: pp. 273-278.
30. Knazovicky D., Tomas A., Motsinger-Reif A., Lascelles B.D. Initial evaluation of nighttime restlessness in a naturally occurring canine model of osteoarthritis pain. Peer J., 2015; vol. 3: e772.
31. Lascelles B.D. Supportive Care for the Cancer Patient. In: Withrow S.J., Vail D.M., Page R.L. (Eds.): Withrow and MacEwen's Small Animal Clinical Oncology (Fifth Edition), W.B. Saunders, St. Luis, 2013; pp.: 245-279.
32. Lascelles B.D., Gaynor J.S., Smith E.S., Roe S.C., Marcellin-Little D.J., Davidson G., Boland E., Carr J. Amantadine in a multimodal analgesic regimen for alleviation of refractory osteoarthritis pain in dogs. J. Vet. Intern. Med., 2008; vol. 22, n. 1: pp. 53-59.
33. Lynch S., Savary-Bataille K., Leeuw B., Argyle D.J. Development of a questionnaire assessing health-related quality-of-life in dogs and cats with cancer. Vet. Comp. Oncol., 2011; vol. 9, n. 3: pp. 172-182.
34. Mohammed S.I., Craig B.A., Mutsaers A.J., Glickman N.W., Snyder P.W., deGortari A.E., Schlittler D.L., Coffman K.T., Bonney P.L., Knapp D.W. Effects of the cyclooxygenase inhibitor, piroxicam, in combination with chemotherapy on tumor response, apoptosis, and angiogenesis in a canine model of human invasive urinary bladder cancer. Mol. Cancer. Ther., 2003; vol. 2, n. 2: pp.183-188.
35. Mondino A., Ludwig C., Menchaca C., Russell K., Simon K.E., Griffith E., Kis A., Lascelles B.D.X., Gruen M.E., Olby N.J. Development and validation of a sleep questionnaire, SNoRE 3.0, to evaluate sleep in companion dogs. Sci. Rep., 2023; vol. 13, n. 1: pp. 13340.
36. Monteiro B.P., Lascelles B.D.X., Murrell J., Robertson S., Steagall P.V.M., Wright B. 2022 WSAVA guidelines for the recognition, assessment and treatment of pain. J. Small Anim. Pract., 2023; vol. 64, n. 4: pp. 177-254.
37. Moore S.A. Managing Neuropathic Pain in Dogs. Front. Vet. Sci., 2016; vol. 3: pp. 12.
38. Nair A.S., Sahoo R.K. Efficacy of Memantine Hydrochloride in Neuropathic Pain. Indian J. Palliat. Care., 2019; vol. 25, n. 1: pp. 161-162.
39. Neufeld N.J., Elnahal S.M., Alvarez R.H. Cancer pain: a review of epidemiology, clinical quality and value impact. Future oncology, 2017; vol. 13, n. 9: pp. 833-841.
40. Noble C.E., Wiseman-Orr L.M., Scott M.E., Nolan A.M., Reid J. Development, initial validation and reliability testing of a web-based, generic feline health-related quality-of-life instrument. J. Feline Med. Surg., 2019; vol. 21, n. 2: pp. 84-94.
41. Parker L.A., Rock E.M., Limebeer C.L. Regulation of nausea and vomiting by cannabinoids. Br. J. Pharmacol., 2011; vol. 163, n. 7: pp. 1411-1422.
42. Pud D., Eisenberg E., Spitzer A., Adler R., Fried G., Yarnitsky D. The NMDA receptor antagonist amantadine reduces surgical neuropathic pain in cancer patients: a double blind, randomized, placebo controlled trial. Pain., 1998; vol. 75, vol. 2-3: pp. 349-354.
43. Quimby J.M., Lorbach S.K., Saffire A., Kennedy A., Wittenburg L.A., Aarnes T.K., Creighton K.J., Jones S.E., Paschall R.E., King E.M., Bruner C.E., Wallinger J.N., van Haaften K.A. Serum concentrations of gabapentin in cats with chronic kidney disease. J. Feline Med. Surg., 2022; vol. 24, n. 12: pp. 1260-1266.
44. Rahn E.J., Deng L., Thakur G.A., Vemuri K., Zvonok A.M., Lai Y.Y., Makriyannis A., Hohmann A.G. Prophylactic cannabinoid administration blocks the development of paclitaxel-induced neuropathic nociception during analgesic treatment and following cessation of drug delivery. Mol. Pain. 2014; vol. 10: pp. 27.
45. Rahn E.J., Makriyannis A., Hohmann A.G. Activation of cannabinoid CB1 and CB2 receptors suppresses neuropathic nociception evoked by the chemotherapeutic agent vincristine in rats. Br. J. Pharmacol., 2007; vol. 152, n. 5: pp. 765-777.
46. Rai A.S., Khan J.S., Dhaliwal J., Busse J.W., Choi S., Devereaux P.J., Clarke H. Preoperative pregabalin or gabapentin for acute and chronic postoperative pain among patients undergoing breast cancer surgery: A systematic review and meta-analysis of randomized controlled trials. J. Plast. Reconstr. Aesthet. Surg., 2017; vol. 70, n. 10: pp. 1317-1328.
47. Ruel H.L.M., Watanabe R., Evangelista M.C., Beauchamp G., Auger J.P., Segura M., Steagall PV. Pain burden, sensory profile and inflammatory cytokines of dogs with naturally-occurring neuropathic pain treated with gabapentin alone or with meloxicam. PLoS One., 2020; vol. 15, n. 11: e0237121.
48. Ruhaak L.R., Felth J., Karlsson P.C., Rafter J.J., Verpoorte R., Bohlin L. Evaluation of the cyclooxygenase inhibiting effects of six major cannabinoids isolated from Cannabis sativa. Biol. Pharm. Bull., 2011; vol. 34, n. 5: pp. 774-778.
49. Savard J., Morin C.M. Insomnia in the context of cancer: a review of a neglected problem. J. Clin. Oncol., 2001; vol. 19, n. 3: pp. 895-908.
50. Savides M.C., Oehme F.W., Nash S.L., Leipold H.W. The toxicity and biotransformation of single doses of acetaminophen in dogs and cats. Toxicol. Appl. Pharmacol., 1984; vol. 74, n. 1: pp. 26-34.
51. Schneider B.M., Dodman N.H., Maranda L. Use of memantine in treatment of canine compulsive disorders. Journal of Veterinary Behavior, 2009; vol. 4, n. 3: pp. 118-126.
52. Shipley H., Flynn K., Tucker L., Wendt-Hornickle E., Baldo C., Almeida D., Allweiler S., Guedes A. Owner evaluation of quality of life and mobility in osteoarthritic cats treated with amantadine or placebo. J. Feline Med. Surg. 2021; vol. 23, n. 6: pp. 568-574.
53. Simone C.B. 2nd, Vapiwala N., Hampshire M.K., Metz J.M. Cancer patient attitudes toward analgesic usage and pain intervention. Clin. J. Pain., 2012; vol. 28, n. 2: pp. 157-162.
54. Steagall P.V., Benito J., Monteiro B.P., Doodnaught G.M., Beauchamp G., Evangelista M.C. Analgesic effects of gabapentin and buprenorphine in cats undergoing ovariohysterectomy using two pain-scoring systems: a randomized clinical trial. J. Feline Med. Surg., 2018; vol. 20, n. 8: pp. 741-748.
55. Taylor S., Gruen M., KuKanich K., Lascelles B.D.X., Monteiro B.P., Sampietro L.R., Robertson S., Steagall P.V. 2024 ISFM and AAFP consensus guidelines on the long-term use of NSAIDs in cats. J. Feline Med. Surg., 2024; vol. 26, n. 4: 1098612X241241951.
56. Tuerxun H., Cui J. The dual effect of morphine on tumor development. Clin. Transl. Oncol., 2019; vol. 21, n. 6: pp. 695-701.
57. Wagner A.E., Mich P.M., Uhrig S.R., Hellyer P.W. Clinical evaluation of perioperative administration of gabapentin as an adjunct for postoperative analgesia in dogs undergoing amputation of a forelimb. J. Am. Vet. Med. Assoc., 2010; vol. 236, n. 7: pp. 751-756.
58. Yazbek K.V., Fantoni D.T. Validity of a health-related quality-of-life scale for dogs with signs of pain secondary to cancer. J. Am. Vet. Med. Assoc., 2005; vol. 226, n. 8: pp. 1354-1358.
TORNA INDIETRO
Patologia comparata del tumore alla prostata del cane e dell'uomo
Sebbene relativamente raro nei cani, il cancro alla prostata (PCa) è il tumore non cutaneo più comune negli uomini. Le ghiandole prostatiche umane e canine condividono molte caratteristiche funzionali, anatomiche e fisiologiche. A causa di queste somiglianze, il PCa canino è stato proposto come modello per il PCa negli uomini.
